CAFI CONSUMER AUTOMOTIVE FIN INC

Fifty 1 Labs, Inc. Accelerates Growth with New CEO, BioSentry Division Launch and Shareholder Dividend; Company Pursues Strategic Growth Through UAV Partnership and Targeted Acquisitions in Advanced Tech and Wellness

Fifty 1 Labs, Inc. Accelerates Growth with New CEO, BioSentry Division Launch and Shareholder Dividend; Company Pursues Strategic Growth Through UAV Partnership and Targeted Acquisitions in Advanced Tech and Wellness

Company Pursues Strategic Growth Through UAV Partnership and Targeted Acquisitions in Advanced Tech and Wellness

MELBOURNE, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (), a leader in innovative technology and wellness solutions, is thrilled to announce that Michael Lawson has assumed the roles of Chief Executive Officer and Chairman of the Board, effective immediately. Mr. Lawson will also spearhead the newly established Fifty 1 Labs BioSentry Division, dedicated to advancing a cutting-edge biohazard sensing sensor technology designed to detect and analyze biological, chemical, and environmental threats in real-time.

The Fifty 1 Labs BioSentry Division will develop state-of-the-art biohazard sensing sensors capable of detecting pathogens (e.g., bacteria, viruses, fungi), biological agents (e.g., anthrax, ricin), chemical contaminants (e.g., heavy metals, cyanotoxins), and hazardous materials (e.g., volatile organic compounds, nerve agents). Leveraging advanced techniques such as polymerase chain reaction (PCR), immunoassays, spectrometry, gas chromatography, and ion mobility spectrometry, the sensors offer:

  • Real-time monitoring with high sensitivity and specificity for rapid threat response.
  • Toxin detection in water sources using electrochemical and optical methods.
  • Compact design for integration with unmanned aerial vehicles (UAVs) for aerial surveillance.
  • IoT-enabled data analytics with AI-driven hazard prediction and mitigation strategies.
  • Environmental resilience for operation in extreme conditions.

The BioSentry technology will empower applications in environmental monitoring (e.g., detecting algae blooms), public health (e.g., identifying airborne pathogens), defense (e.g., chemical weapons detection), and industrial safety (e.g., hazardous material leaks), positioning Fifty 1 Labs as a trailblazer in advanced sensor solutions.

Fifty 1 Labs is also excited to announce a strategic partnership with UAV Corp (OTC: UMAV) to advance UAV-integrated biohazard detection capabilities. As part of this collaboration, Fifty 1 Labs plans to issue a dividend of UMAV shares to FITY shareholders, strengthening alignment between the companies and their investors. Details of the dividend will be shared in the coming months.

Leadership Transition and Shareholder Alignment

It was previously announced that Genetic Networks LLC had been acquired by Fifty 1 Labs, Inc. However, after the 30-day due diligence process, the acquisition was not finalized and the Board of Directors and shareholder majority felt it was in the best interest of the shareholders not to move forward. In connection with this decision, Fifty 1 Labs confirms that Gennaro D'Urso's employment agreement was never signed and the offer of employment was rescinded. The company extends its best wishes to Mr. D'Urso in his future endeavors.

Strategic Focus and Continued Leadership

Fifty 1 Labs will be working to secure multi-million-dollar Department of Defense (DoD) contracts as part of its growth strategy, leveraging the capabilities of its BioSentry technology and UAV integration initiatives. Brandon Spikes will continue in his role as President and Director, overseeing 51 LLC, FITY's sports and wellness division. In addition, Robert Clark will remain with the company as a member of its Board of Directors, providing continued strategic guidance as Fifty 1 Labs advances its mission.

"Michael Lawson's leadership marks an exciting chapter for Fifty 1 Labs as we innovate in biohazard detection and deliver value to our shareholders," said a company spokesperson. "Our partnership with UAV Corp and the launch of the Fifty 1 Labs BioSentry Division, alongside our premium supplement line, underscore our commitment to addressing global safety and wellness challenges with groundbreaking solutions."

For more information, please visit

About Fifty 1 Labs, Inc.

Fifty 1 Labs, Inc. (OTC: FITY) is a technology and wellness company focused on developing cutting-edge solutions for public safety, environmental monitoring, industrial applications, and personal health. The Fifty 1 Labs BioSentry Division is advancing a cutting-edge biohazard sensing sensor technology designed to detect and analyze biological, chemical, and environmental threats in real-time. Through its subsidiary, 51 LLC, the company offers a premium line of supplements, including pre-workout formulas, BCAAs, ION+ Electrolyte Formulas, Turmeric Gummies, and Ashwagandha Gummies. With a commitment to innovation and shareholder value, Fifty 1 Labs is dedicated to addressing global challenges through advanced technology and wellness solutions.

Contact: Investor Relations Fifty 1 Labs, Inc.

Email:

Phone:

About UAV Corp.

UAV Corp. (OTC: UMAV) is a Wyoming-based innovator in advanced aerial systems, delivering cutting-edge solutions for defense, logistics, and emergency response. With a focus on growth and technological leadership, UAV Corp. is committed to creating shareholder value and pursuing a Nasdaq uplisting.

Contact: Michael Lawson, CEO

Email:

Phone: (877) 425-1066

115 County Road 381, Wewahitchka, FL 32465

 

Safe Harbor Statement:

The information provided in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Identifiable by words such as "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, these statements may also be made in written or oral form in the company's filings with the U.S. Securities and Exchange Commission, OTC Markets, press releases, other written materials, or in oral statements made by its officers, directors, or employees to third parties. There can be no assurance that such statements will prove to be accurate. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Disclosure Statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the company's control. The company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.

Wire Service Contact:

IBN

Austin, Texas



512.354.7000 Office



EN
30/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONSUMER AUTOMOTIVE FIN INC

 PRESS RELEASE

Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment P...

Fifty1 Labs, Inc. and BioSpark AI Unlock 2,000+ Real-World Treatment Pathways to Accelerate Functional Medicine Innovation Strategic partnership and planned acquisition position Fifty1 Labs to dominate AI-driven drug repurposing and wellness therapeutics at scale VANCOUVER, British Columbia and PALO ALTO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- via IBN --  Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (), together with its commercial partner BioSpark AI Technologies Inc., is announcing a major milestone in its AI-driven drug repurposing and functional medicine initiative. The joi...

 PRESS RELEASE

Fifty 1 Labs, Inc. Hosts Successful Virtual Shareholder Teleconference...

Fifty 1 Labs, Inc. Hosts Successful Virtual Shareholder Teleconference, Showcasing AI-Driven Functional Medicine Strategy and World-Class Leadership SEATTLE, July 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (), a pioneer in AI-powered health and wellness solutions, successfully hosted its virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST via X (formerly Twitter). The event drew significant engagement from shareholders and stakeholders, providing a comprehensive overview of the company's transformative growth strategy through its subsidiary, Fifty ...

 PRESS RELEASE

Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featurin...

Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. (), a leader in AI-powered health and wellness solutions, today announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event will be broadcast on X (formerly Twitter), featuring Nobel Peace Prize recipient Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf o...

 PRESS RELEASE

Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: ...

Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies SEATTLE, July 17, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, an innovative subsidiary of Fifty 1 Labs, Inc. (), is thrilled to announce a strategic partnership with an intent to acquire BioSpark AI Technologies Inc., a Vancouver-based pioneer in advanced AI and large language model (LLM) technologies. Revealed today, this alliance is set to transform drug repurposing by leveraging cutting-edge AI to un...

 PRESS RELEASE

Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, ...

Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership Pioneering a New Era in Healthcare: AI-Driven Innovation Unlocks Transformative Therapies and Drives Path to $50M Valuation SEATTLE, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, a wholly owned subsidiary of Fifty 1 Labs, Inc. (), in collaboration with premier academic institutions including Stanford University, Duke University, McMaster University (Canada), and global partners, prou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch